ArticleFrontiers in bioengineering and biotechnology2025
New applications of sustainable, scalable, standardized, and cost-effective human biomaterials for cell-based assays, tissue engineering, and regenerative medicine.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human-derived biomaterials offer several advantages over animal-derived or synthetic alternatives, including improved biocompatibility, ethical acceptability, sustainability, and clinical translatability. Here we present new applications of human placenta-derived materials - specifically HUMAN PLACENTA substrate, collagen type-I, and Laminin-111 - as 2D coating materials and 3D matrices for the cultivation of spheroids and adherent cells. Collagen type-I coatings supported colorectal cancer spheroid formation without the need for growth-factor supplementation. Lm-111 significantly enhanced NIH3T3 fibroblast adhesion compared with poly-L-lysine and rat-tail collagen type-I, performing comparably to bovine fibronectin. In a transwell blood-brain barrier model, HUMAN PLACENTA substrate coatings enabled confluent endothelial monolayers with transendothelial electrical resistance values not significantly different from the conventional human collagen type-IV/bovine fibronectin mixture. Across these
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.